Toward a Computationally-Informed, Personalized Treatment for Hallucinations

Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18-65
SponsorYale University

About this trial

Auditory hallucinations are among the most distressing aspects of psychotic illness, and between 10 and 30% of people with hallucinations do not respond to antipsychotic medications. The authors have used computational modeling of behavior to link brain activity to development of auditory hallucinations in the hope of guiding new treatment development. The proposed studies take the first step toward individualized treatment approaches to hallucinations by attempting causal, pharmacological manipulation of relevant model parameters underlying these phenomena.

Eligibility criteria

Qualifiers

Age 18-65

English speaking

Right handedness

Diagnosed with schizophrenia schizoaffective, schizophreniform, schizotypal, or brief psychotic disorder

Disqualifiers

Current substance dependence or active use as determined by drug test.

Any neurological, medical or developmental problem that is known to impair cognition significantly

Contraindications for MR scanning including metallic implants of any kind, pacemakers and history of accidents with metal, claustrophobia

History of seizures

Trial design

Treatments tested in this trial

  • Rivastigmine Transdermal System
  • Scopolamine
  • Placebo Patch
  • Placebo Patch

Treatment groups

35 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Yale University

Lead sponsor

National Institute of Mental Health (NIMH)

Collaborator